公开(公告)号：US12129495B2

公开(公告)日：2024-10-29

申请号：US18046895

申请日：2022-10-14

Applicant: Codexis, Inc.

Inventor： Ericka Bermudez ,  David Elgart ,  Nikki D. Kruse ,  Mathew G. Miller ,  Vesna Mitchell ,  Jovana Nazor ,  Nandhitha Subramanian

IPC: C12N9/10 ,  C12N9/12 ,  C12N15/63

CPC classification number: C12N9/1252 ,  C12N15/63 ,  C12Y207/07007

Abstract: The present disclosure relates to engineered DNA polymerase polypeptides and compositions thereof, as well as polynucleotides encoding the engineered DNA polymerase polypeptides. The present disclosure also provides methods of using the engineered DNA polymerase polypeptides or compositions thereof for diagnostic and other purposes.

公开(公告)号：US20240344043A1

公开(公告)日：2024-10-17

申请号：US18628400

申请日：2024-04-05

Applicant: LifeEDIT Therapeutics, Inc.

Inventor： Tyson D. Bowen ,  Alexandra Briner Crawley ,  Tedd D. Elich

IPC: C12N9/22 ,  C12N15/63

CPC classification number: C12N9/22 ,  C12N15/63 ,  C12N2310/20 ,  C12N2800/80

Abstract: Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.

公开(公告)号：US20240336906A1

公开(公告)日：2024-10-10

申请号：US18627839

申请日：2024-04-05

Applicant: LifeEDIT Therapeutics, Inc.

Inventor： Tyson D. Bowen ,  Alexandra Briner Crawley ,  Tedd D. Elich

IPC: C12N9/22 ,  C12N15/63

CPC classification number: C12N9/22 ,  C12N15/63 ,  C12N2310/20 ,  C12N2800/80

Abstract: Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.

公开(公告)号：US20240317863A1

公开(公告)日：2024-09-26

申请号：US18637522

申请日：2024-04-17

Applicant: Oricell Therapeutics Co., Ltd.

Inventor： Bohua LI ,  Huajing WANG ,  Xiaowen HE

IPC: C07K16/28 ,  A61K31/713 ,  A61K39/00 ,  A61P35/00 ,  C12N5/10 ,  C12N15/63

CPC classification number: C07K16/2827 ,  A61K31/713 ,  A61P35/00 ,  C07K16/2878 ,  C07K16/2896 ,  C12N5/10 ,  C12N15/63 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76

Abstract: An antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. The antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody may be used in the prevention and treatment of tumors.

公开(公告)号：US20240316123A1

公开(公告)日：2024-09-26

申请号：US18616811

申请日：2024-03-26

Applicant: ZBiotics Company

Inventor： Zachary Abbott

IPC: A61K35/742 ,  A61K9/00 ,  A61K35/00 ,  A61K35/741 ,  A61K38/00 ,  A61P39/02 ,  C07K14/32 ,  C12N9/02 ,  C12N15/63

CPC classification number: A61K35/742 ,  A61K9/0053 ,  A61P39/02 ,  C07K14/32 ,  C12N9/0008 ,  C12N15/63 ,  C12Y102/01003 ,  A61K9/0095 ,  A61K2035/115 ,  A61K35/741 ,  A61K38/00

Abstract: Provided herein are recombinant microorganisms that express a subject polypeptide. Microorganisms can comprise an expression construct comprising a flagellin promoter operatively linked with a heterologous nucleotide sequence encoding the subject polypeptide. The flagellin promoter sequence can comprise a genetic modification that reduces CsrA inhibition of translation. Microorganisms also can comprise a genetic modification that reduces FlgM inhibition of SigD initiation of transcription. The target polypeptide can be an aldehyde dehydrogenase. Such microorganisms are useful in the treatment of alcohol hangover.

公开(公告)号：US12091441B2

公开(公告)日：2024-09-17

申请号：US17320174

申请日：2021-05-13

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Inventor： Kenan Christopher Garcia ,  Sonia S. Majri ,  Caleb R. Glassman ,  Leon Lih-Ren Su

IPC: A61K38/20 ,  A61P37/00 ,  C07K14/55 ,  C07K16/24 ,  C12N15/63 ,  A61K9/00 ,  A61K38/00

CPC classification number: C07K14/55 ,  A61P37/00 ,  C07K16/244 ,  C12N15/63 ,  A61K9/0024 ,  A61K38/00 ,  C07K2317/74 ,  C07K2317/92 ,  C07K2319/30 ,  C07K2319/31

Abstract: Provided herein, inter alia, are human interleukin-2 (IL-2) muteins or variants thereof. In particular, provided herein are IL-2 muteins that have a decreased binding capacity for IL-2Rγ. Such IL-2 muteins are useful, for example, as IL-2 partial agonist in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of autoimmune diseases or conditions). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

公开(公告)号：US20240294890A1

公开(公告)日：2024-09-05

申请号：US18649077

申请日：2024-04-29

Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Inventor： Omar Abudayyeh ,  Jonathan Gootenberg

IPC: C12N9/22 ,  A61K38/00 ,  A61K48/00 ,  C12N9/78 ,  C12N15/10 ,  C12N15/11 ,  C12N15/63 ,  C12Q1/6825

CPC classification number: C12N9/22 ,  A61K48/005 ,  C12N9/78 ,  C12N15/102 ,  C12N15/11 ,  C12N15/63 ,  C12Y305/04004 ,  C12Y305/04005 ,  A61K38/00 ,  C07K2319/85 ,  C12N2310/20 ,  C12N2320/10 ,  C12N2320/33 ,  C12Q1/6825

Abstract: This disclosure provides systems, methods, and compositions for RNA-guided RNA-targeting CRISPR effectors for the treatment of diseases as well as diagnostics. In some embodiments, nucleotide deaminase functionalized CRISPR systems for RNA editing RNA knockdown, viral resistance, splicing modulation, RNA tracking, translation modulation, and epi-transcriptomic modifications are disclosed.

公开(公告)号：US20240294663A1

公开(公告)日：2024-09-05

申请号：US18659507

申请日：2024-05-09

Applicant: Link (Assignment for the Benefit of Creditors), LLC

Inventor： Colin Correnti ,  Christopher Mehlin ,  David Meininger ,  Ashok Bandaranayake

IPC: C07K16/30 ,  A61P35/00 ,  C07K16/46 ,  C12N15/63

CPC classification number: C07K16/30 ,  A61P35/00 ,  C07K16/468 ,  C12N15/63 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: The present disclosure provides antibodies and polypeptides that specifically bind to mesothelin (MSLN), including bispecific antibodies that bind both MSLN and a T cell antigen (e.g., CD3). Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

公开(公告)号：US12071459B2

公开(公告)日：2024-08-27

申请号：US17717120

申请日：2022-04-10

Applicant: ZHEJIANG RISING BIOTECHNOLOGY CO., LTD.

Inventor： Jianxin Cao

IPC: C12N15/63 ,  C07K1/18 ,  C07K14/51 ,  C12N15/09 ,  C12N15/66 ,  C07K1/14 ,  C07K1/16

CPC classification number: C07K14/51 ,  C07K1/18 ,  C07K1/14 ,  C07K1/16 ,  C12N15/09 ,  C12N15/63 ,  C12N15/66

Abstract: The present invention relates to a field of biotechnology. It discloses a novel amino acid sequence of recombinant human bone morphogenetic protein-2 (rhBMP-2) and encoded nucleotide sequences thereof, and a method for preparing rhBMP-2. In the present invention, by further optimizing the nucleotide sequence of rhBMP-2, novel amino acid sequence of rhBMP-2 that can express good ectopic induced osteogenic activity and has good renaturation and purification effect is screened out. The engineered bacteria constructed by the present invention can induce the production of recombinant rhBMP-2 protein with an expression level of about 55%, and the produced target protein is more easily denatured and purified than the existing recombinant rhBMP-2, with better denaturation and purification effect and higher osteoinductive activity.

公开(公告)号：US20240279349A2

公开(公告)日：2024-08-22

申请号：US17836473

申请日：2022-06-09

Applicant: Sanjaya Singh ,  Alisa Waterman ,  Erik Depla ,  Toon Laeremans ,  Diane Van Hoorick ,  Cedric Ververken

Inventor： Sanjaya Singh ,  Alisa Waterman ,  Erik Depla ,  Toon Laeremans ,  Diane Van Hoorick ,  Cedric Ververken

IPC: C07K16/28 ,  C07H21/04 ,  C12N15/09 ,  C12N15/11 ,  C12N15/63 ,  A61K39/00 ,  A61K39/395 ,  A61P13/12 ,  C07K14/52 ,  C07K14/715

CPC classification number: C07K16/2866 ,  C07H21/04 ,  C07K16/28 ,  C12N15/09 ,  C12N15/11 ,  C12N15/63 ,  A61K39/3955 ,  A61K2039/505 ,  A61P13/12 ,  C07K14/521 ,  C07K14/7158 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30

Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.